

16 February 2018

Scancell Holdings Plc
("Scancell" or the "Company")

Scancell to present at the Calculus Investor Forum

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Cliff Holloway, Chief Executive Officer and Lindy Durrant, Chief Scientific Officer, have been invited to present an overview of the Company alongside recognised experts in the fields of melanoma, lung cancer and the development of innovative immunotherapies, at the Calculus Investor Forum in London on Friday 16 February 2018 at 12.15pm GMT.

A PDF of the presentation will be available on the investors section of the Scancell website at the same time and a recording will be available thereafter. There will be no material information presented that is not already in the public domain.

For Further Information:

Scancell

Dr John Chiplin, Chairman Dr Cliff Holloway, CEO	Scancell Holdings Plc	+1 858 361 6288
Freddy Crossley (Corporate Finance) Tom Salvesen (Corporate Broking)	Panmure Gordon & Co	+44 (0) 20 7886 2500
Mo Noonan/Simon Conway	FTI Consulting	+44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours with minimal toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.